These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38751292)

  • 1. Anti-programmed-death-receptor-1 (PD-1) antibody (Pembrolizumab) induced pancreatitis diagnosed on 18F-FDG PET/CT.
    Usmani S; Jain A; Riyami KA; Sayani R; Jayakrishnan VV
    J Pak Med Assoc; 2024 Apr; 74(4):825-826. PubMed ID: 38751292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.
    Alabed YZ; Aghayev A; Sakellis C; Van den Abbeele AD
    Clin Nucl Med; 2015 Nov; 40(11):e528-9. PubMed ID: 26284765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT.
    Das JP; Halpenny D; Do RK; Ulaner GA
    Clin Nucl Med; 2019 Oct; 44(10):836-837. PubMed ID: 31283599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET/CT.
    Pereira M; Prakash A; Puranik AD; Purandare N; Shah S; Agrawal A; Rangarajan V
    Clin Nucl Med; 2021 May; 46(5):e256-e257. PubMed ID: 33315679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab-Induced Thyroiditis and Colitis-Presentation and Resolution on Serial FDG PET/CT.
    Nawwar AA; Searle J; Lyburn ID
    Clin Nucl Med; 2021 Feb; 46(2):e121-e122. PubMed ID: 32969909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Urol Oncol; 2021 Apr; 39(4):235.e15-235.e21. PubMed ID: 33071107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organ-specific accuracy of [
    Gideonse BM; Birkeland M; Vilstrup MH; Grupe P; Naghavi-Behzad M; Ruhlmann CH; Gerke O; Hildebrandt MG
    Jpn J Radiol; 2024 Jul; 42(7):753-764. PubMed ID: 38504000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.
    Anderson TM; Chang BH; Huang AC; Xu X; Yoon D; Shang CG; Mick R; Schubert E; McGettigan S; Kreider K; Xu W; Wherry EJ; Schuchter LM; Amaravadi RK; Mitchell TC; Farwell MD
    Clin Cancer Res; 2024 May; 30(9):1758-1767. PubMed ID: 38263597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy (Cemiplimab)-Induced Bullous Pemphigoid: A Possible Pitfall in 18F-FDG PET/CT.
    Grünig H; Skawran SM; Nägeli M; Kamarachev J; Huellner MW
    Clin Nucl Med; 2022 Feb; 47(2):185-186. PubMed ID: 34507324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
    Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis.
    Luo P; Guo Y; He Y; Wang C
    Invest New Drugs; 2024 Aug; 42(4):369-375. PubMed ID: 38829427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
    Valentinuzzi D; Vrankar M; Boc N; Ahac V; Zupancic Z; Unk M; Skalic K; Zagar I; Studen A; Simoncic U; Eickhoff J; Jeraj R
    Radiol Oncol; 2020 Jul; 54(3):285-294. PubMed ID: 32726293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
    Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Cancer Complicated by Pancreatitis Demonstrated on FDG PET/CT.
    Hennessy G; Vamadevan S; Loh H; Bui C; Le K; Mansberg R
    Clin Nucl Med; 2017 Mar; 42(3):239-240. PubMed ID: 28098664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim [
    Sachpekidis C; Kopp-Schneider A; Pan L; Papamichail D; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1932-1943. PubMed ID: 33336264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
    Mekki A; Dercle L; Lichtenstein P; Marabelle A; Michot JM; Lambotte O; Le Pavec J; De Martin E; Balleyguier C; Champiat S; Ammari S
    Eur J Cancer; 2018 Jun; 96():91-104. PubMed ID: 29698933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
    Wachsmann JW; Ganti R; Peng F
    Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.